Episode 04 · Longevity
Hitting undo on aging
Scientists think part of aging is a “software” glitch — and they just got the first green light to try rebooting it in people.
Prof. David Sinclair's lab (Harvard Medical School) & Life Biosciences · Harvard Medical School & Life Biosciences
Peer-reviewed in Nature (2020) · Science published in Nature (2020) · first human trial FDA-cleared (2026)
Watch & listen
Video brief
Plain-language · ~2 min
Audio brief
Single host · 2:01
Voices and visuals in these briefs are AI-generated.
At a glance
The whole study in one picture.
Read it 3 ways
Same research, three lenses — pick yours.
What if a big part of aging isn't your body wearing out, but your cells “forgetting” how to be young?
Think of your DNA as the hardware and the epigenome as the software — the settings telling each cell which genes to switch on. Over time, that software gets noisy. Researchers found that briefly switching on a trio of “reset” genes (the Yamanaka factors, used here as OSK) can roll the software back toward youth without erasing the cell's job. In mice, this restored vision in glaucoma and aged eyes. In January 2026, the FDA cleared the first human trial — starting with an eye condition.
Keep your feet on the ground, though. Most of the evidence is in mice; the human trial is small, early, and aimed at one disease — not whole-body youth. Push the “reset” too far and cells lose their identity, which is why it's done partially.
Jargon decoder
Epigenome
The cell's “software” — chemical tags that decide which genes are on or off.
Epigenetic reprogramming
Resetting those tags toward a younger pattern.
Yamanaka factors (OSK)
Genes (Oct4, Sox2, Klf4) that can rewind a cell's biological clock.
Partial reprogramming
Rewinding only part-way, so the cell stays itself but acts younger.
Information theory of aging
The idea that aging is lost “software” information, not just broken hardware.
Glaucoma
An eye disease that damages the optic nerve and can cause blindness.
Clinical trial (IND)
An approved test of a treatment in people, starting with safety.
Cellular identity
The “job” a cell holds (e.g., a skin cell vs a nerve cell) — risky to erase.
Keep in mind
Most results are in mice. The first human trial is small, early, and aimed at a single eye disease — not a whole-body anti-aging cure. Promising, but unproven in people.
Sources
Curated by K² Series. Voices and visuals in the briefs are AI-generated — always double-check before relying on them.